PE-22-28

Peptide Sciences USA
  • Active Substance: PE-22-28 (Spadin Derivative)
  • Concentration: 8 mg per vial
  • Pack Size: Single vial (lyophilized powder)
  • Manufacturer: Peptide Sciences USA
  • Brand Name: PE-22-28
  • Molecular Formula: C35H55N11O9
  • Molecular Weight: ~797.9 g/mol (estimated)
  • Sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg-OH
  • Synonyms: Spadin Analog, TREK-1 Inhibitor
Manufacturer Peptide Sciences USA
Brand PE-22-28
Substance PE-22-28
Concentration 8 mg
Pack Size vial
Out of Stock

PE-22-28 8 mg – Spark of Neural Renewal

Spark Your Depression Research

Imagine a lab where mood lifts, neurons regenerate, and depression fades faster than ever. PE-22-28 8 mg from Peptide Sciences USA makes this real. This spadin-derived peptide inhibits TREK-1 channels, doubling neurogenesis and synaptogenesis in just 4 days, driving breakthroughs in depression and neuroprotection research. It's your spark for leading transformative studies, crafted for trailblazing researchers like you.

The Science Behind Neural Renewal

PE-22-28 (sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg-OH) is a 7-amino-acid synthetic derivative of spadin, a sortilin-derived peptide that potently inhibits TREK-1 (KCNK2) potassium channels (IC50: 0.12 nM). By blocking TREK-1 in brain regions like the hippocampus and prefrontal cortex, it enhances neuronal excitability and serotonin signaling. In mouse models, PE-22-28 doubled BrdU-positive cells (neurogenesis marker) and synapse formation after 4 days, compared to 2–4 weeks for traditional antidepressants.

It also increases CREB, a transcription factor linked to memory and neuroplasticity, per [web:0,10]. PE-22-28's stability (up to 23 hours vs. spadin's 7 hours) makes it ideal for studying depression, stroke recovery, Alzheimer's, and neuroprotection. The 8 mg injectable dosage offers high bioavailability for rapid-onset research into mood regulation and neural repair.

Why PE-22-28 8 mg Fuels Your Studies

PE-22-28 isn't just a peptide—it's a spark that transforms depression research. Here's what makes it shine:

  • Rapid Antidepressant Action: Reduces immobility in forced swim tests within 4 days.
  • Neurogenesis Boost: Doubles BrdU-positive cells in the hippocampus.
  • Synaptogenesis Support: Enhances synapse formation by 2x in preclinical models.
  • Neuroprotection Potential: Protects against stroke and Alzheimer's pathology.
  • Top Quality: Crafted by Peptide Sciences USA with 99% purity for reliable results.

With PE-22-28 8 mg, you're not just studying—you're leading a breakthrough in neural renewal and mental health.

Product Specifications

Peptide Sciences USA's PE-22-28 8 mg is your key to cutting-edge depression studies. Here's the breakdown:

  • Composition: Contains 8 mg PE-22-28 (C35H55N11O9, ~797.9 g/mol).
  • Pack Size: Single vial of lyophilized powder, requiring reconstitution for subcutaneous or intravenous injection.
  • Manufacturing: Produced by Peptide Sciences USA with 99% purity, verified by HPLC and Mass Spectrometry, per [web:0,4].
  • Usage Guidelines: Reconstitute with 1–2 mL bacteriostatic water (4–8 mg/mL). Inject 100–200 mcg (0.1–0.2 mg) subcutaneously or intravenously daily for 4–14 days in research protocols, per [web:7,11]. Use under professional supervision.
  • Storage: Store lyophilized powder at -20°C for long-term stability or 4°C for short-term use (up to 3–4 weeks). After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks.
  • Safety: Preclinical studies report minimal side effects, with no significant TREK-1-related adverse effects; limited human data requires oversight.

This peptide is for research purposes only, driving discoveries in depression and neuroprotection.

Frequently Asked Questions

What is PE-22-28 peptide?

PE-22-28 is a 7-amino-acid spadin derivative that inhibits TREK-1 channels, promoting neurogenesis and antidepressant effects.

What are the benefits of PE-22-28 in research?

It boosts neurogenesis, synaptogenesis, and mood, with potential in depression, stroke, and Alzheimer's studies.

How is PE-22-28 8 mg administered in research?

Mix the 8 mg vial with 1–2 mL bacteriostatic water. Inject 100–200 mcg subcutaneously or intravenously daily for 4–14 days.

What are the potential side effects of PE-22-28?

Preclinical studies report minimal side effects, with no significant TREK-1-related adverse effects; limited human data requires oversight.

How does PE-22-28 support depression treatment?

It inhibits TREK-1, enhancing serotonin signaling and neurogenesis, reducing depressive behaviors in 4 days.